// App-Quantinova.ai

621 : Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

Researchers

Presenter

  • Jordi Rodon Ahnert

Principal Investigators

  • Jean-Pascal H. Machiels

  • Catherine Herremans

  • Markus Joerger

  • Jesus Corral Jaime

  • Maria Alsina

  • Fabienne Baffert

  • David Demanse

  • Vincent Duval

  • Alex Morozov

  • Ahmad Awada

  • Roger von Moos

  • Neeltje Steeghs

  • Cristina Cruz Zambrano

  • Peggy De Mesmaeker

  • Heike Richly

  • Luc Dirix

  • Dagmar Hess

  • Luis Paz-Ares

Medical Centers

  • Sint-Augustinus Hospital, Antwerpen, Belgium

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium

  • Cantonal Hospital, St. Gallen, SwitzerlandThe Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, NetherlandsNovartis Pharma AG, Basel, Switzerland

  • Universitary Hospital Virgen del Rocio, Sevilla, Spain

  • West German Cancer Center, University Hospital, Essen, Germany

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium

  • Cantonal hospital of Graubunden, Chur, Switzerland

Locations

  • Spain

  • Germany

  • Switzerland

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • Paclitaxel

  • BEZ235

Outcome

  • Negative

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01285466

Sponsors

  • Novartis

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved